Andrea WONG

Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom. She specializes in breast cancer and neuro-oncology, and actively contributes to cancer research through her involvement as a Principal Investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS). She is a member of the NCIS early phase clinical trial cancer drug development team, and is also involved in translational research work in conjunction with the development of novel targeted therapies for the treatment of advanced cancer. She has been awarded several research grants in the past and is currently the Principal Investigator of the National Medical Research Council New Investigator Grant Award. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the American Society of Clinical Oncology and the Singapore Society of Oncology.

Special interest in:

1) Early phase clinical trials
2) Breast cancer therapeutic studies
3) Biomarker development studies
4) Translational research involving novel therapeutics (STAT3 and oxidative phosphorylation inhibitors)

 Selected Publications:

  1. A Wong, R Soo, D Tan, SC Lee, J Lim, P Marban, LR Kong, YJ Lee, LZ Wang, WL Thuya, R Soong, MQ Yee, TM Chin, MT Cordero, BR Asuncion, B Pang, S Pervaiz, JL Hirpara, A Sinha, WW Xu, M Yuasa, T Tsunoda, M Motoyama, T Yamauchi, BC Goh, ‘Phase I and Biomarker Study of OPB-51602, a Novel Signal Transducer and Activator of Transcription (STAT) 3 Inhibitor, in Patients with Refractory Solid Malignancies’. Annals of Oncology (2015), 26 (5): 998-1005.
  2. A Wong, J Lim, A Sinha, A Gopinathan, R Lim, CS Tan, T Soh, S Venkatesh, C Titin, NS Sapari, SC Lee, WP Yong, D Tan, B Pang, TT Wang, YK Zee, R Soong, Z Trnkova, C Lathia, S Wilhelm, M Jeffers and BC Goh. ‘Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib’. Journal of Translational Medicine (2015); 13: 57 Doi: 1186/s12967-015-0405-4
  3. A Wong, KY Seng, E Ong, LZ Wang, H Oscar, M Cordero, R Copones, L Fan, SH Tan, BC Goh, SC Lee. ‘Body composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients’. Breast Cancer Research and Treatment (2014). DOI 10.1007/s10549-014-2843-8
  4. A Wong, SC Lee. ‘Mechanisms of resistance to trastuzumab and novel therapeutic strategies in the management of HER-2 positive breast cancer’. International Journal of Breast Cancer (2012) Article 415170
  5. LZ Wang, , SH Goh, A Wong, WL Thuya, JY Lau, SC Lee, BC Goh, ‘Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study. PLoS One. 2015; 10(3): e0118553
  6. Lau V, A Wong, Ng C, Mok Y, Lakshmanan, Yan B. “Drug sensitivity testing platforms for gastric cancer diagnostics.” J Clin Pathol 2015 doi: 10.1136/jclinpath-2015-203426
  7. N Ngoi, SC Lee, M Hartman, LW Khin, A Wong. ‘Interest and Attitudes of Patients, Cancer Physicians, Medical Students and Cancer Researchers towards a Spectrum of Genetic Tests Relevant to Breast Cancer Patients’. The Breast (2012) DOI:10.1016/j.breast.2012.04.003
  8. PJ Voon, HL Yap, CY Ma, L Fan, A Wong, N Sapari, R Soong, T Soh, BC Goh, HS Lee, SC Lee. ‘Correlation of Aldo-ketoreductase (AKR) 1C3 Genetic Variants with Doxorubicin Pharmacodynamics in Asian Breast Cancer Patients’. British J Clin Pharmacol (2012), doi: 10.1111/ bcp.12021
  9. LZ Wang, T Ramirez, W Yeo, MM Chan, WL Thuya, JY Lau, SC Wan, A Wong, YK Zee, R Lim, SC Lee, P Ho, HS Lee, A Chan, S Ashner, M Ratain, BC Goh. ‘Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of Belinostat in liver cancer patients.’ PloS One (2013); 8(1): e54522
  10. LZ Wang, R Ong, TM Chin, WL Thuya, SC Wan, A Wong, SY Chan, P Ho, BC Goh. ‘Method development and validation for quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry’. Journal of Pharmaceutical and Biomedical Analysis (2012) 61: 86-92
Name Andrea Li Ann WONG
Affiliations Principal Associate, Cancer Science Institute of Singapore, NUS
Consultant, Department of Haematology-Oncology, National Cancer Institute of Singapore, National University Health System
Email Andrea_LA_Wong[at]


Institute Degree (if applicable) Year(s)
Royal College of Physicians (UK) MRCP (UK), M Med (Int Med) 2006
University of Glasgow MBChB (Hons) 2002

Professional Experience

Department of Haematology-Oncology, NUHS 2007-current
NHG Medical Officer 2003-2006